- ►healtoronto.com [PDF] J Fellay, B Ledergerber, E Bernasconi, H … - The Lancet, 2001 - Elsevier 47% (545 of 1160) of patients presented with clinical and 27% (194 of 712) with
laboratory adverse events probably or definitely attributed to antiretroviral
treatment. Among these, 9% (47 of 545) and 16% (30 of 194), respectively, ... Cited by 241 - Related articles - BL Direct - All 11 versions
E Martinez, JA Arnaiz, D Podzamczer, D Dalmau … - New England Journal of Medicine, 2003 - content.nejm.org Results At 12 months, the Kaplan–Meier estimates of the likelihood of reaching
the end point were 10 percent in the nevirapine group, 6 percent in the
efavirenz group, and 13 percent in the abacavir group (P=0.10 according to ... Cited by 199 - Related articles - BL Direct - All 7 versions
TR Sterling, D Vlahov, J Astemborski, DR … - The New England journal of medicine, 2001 - nejm.highwire.org Results The median initial viral load was 50,766 copies of HIV-1 RNA per
milliliter in the men but only 15,103 copies per milliliter in the women
(P<0.001). The median initial CD4+ count did not differ significantly ... Cited by 189 - Related articles - BL Direct - All 8 versions
M Lipsitch, MH Samore, 2002 - pubmedcentral.nih.gov The need to stem the growing problem of antimicrobial resistance has prompted
multiple, sometimes conflicting, calls for changes in the use of antimicrobial
agents. One source of disagreement concerns the major mechanisms by which ... Cited by 137 - Related articles - BL Direct - All 13 versions
- ►adisonline.com [PDF] E Martinez, MA Garcia-Viejo, J Blanch, JM … - Drug Safety, 2001 - ingentaconnect.com Abstract Current antiretroviral therapy has lead to longer survival in patients
infected with HIV, but it is also associated with new and important problems.
Body fat redistribution and metabolic abnormalities, the so-called ... Cited by 82 - Related articles - BL Direct - All 7 versions
CR Fumaz, A Tuldra, MJ Ferrer, R Paredes, A … - JAIDS Journal of Acquired Immune Deficiency …, 2002 - journals.lww.com We assessed the impact of an efavirenz-containing regimen versus a protease
inhibitor-containing regimen on quality of life, emotional status, and adherence
of HIV-1-infected patients. In addition, we sought to define the adverse ... Cited by 65 - Related articles - BL Direct - All 8 versions
- ►psu.edu [PDF] BR Schackman, KA Freedberg, MC Weinstein, … - Archives of Internal Medicine, 2002 - Am Med Assoc You are seeing this message because your Web browser does not support basic Web
standards. Find out more about why this message is appearing and what you can do
to make your experience on this site better. Cited by 51 - Related articles - BL Direct - All 8 versions
AW Wu - Aids, 2000 - journals.lww.com There are questions about the treatment of HIV/AIDS that can only be answered by
asking the patient. Some of the questions are clinically important, such as:
among treatments that are equivalent in terms of virologic and immunologic ... Cited by 53 - Related articles - BL Direct - All 4 versions
R Murri, M Fantoni, C Del Borgo, R Visona, A … - AIDS care, 2003 - ingentaconnect.com In the era of new antiretroviral treatments that have dramatically reduced both
morbidity and mortality, a primary goal is to maximize function and wellbeing in
the everyday life of HIV-infected patients. To be able to do so, it would ... Cited by 51 - Related articles - BL Direct - All 4 versions
- ►hawaii.edu [PDF] M Rabkin, W El-Sadr, DA Katzenstein, J … - The Lancet, 2002 - Elsevier Data lending support to use of antiretroviral treatment in poorly resourced
regions are few. Even in well resourced countries, clinicians still do not have
evidence-based answers to simple issues such as: when to start ... Cited by 51 - Related articles - All 9 versions
